Shize Biopharmaceuticals

Shize Biopharmaceuticals (XellSmart) is a clinical-stage biotechnology company based in China that specializes in the development of allogeneic, off-the-shelf iPSC-derived cell therapies for neurodegenerative diseases. Founded in 2021 by Dr. Michael Lee, the company has established a robust platform for iPSC reprogramming, gene editing, and large-scale differentiation into specific neural subtypes. Its lead programs, including XS-411 for Parkinson's disease and XS-228 for ALS, have received IND clearances from both the US FDA and China's NMPA. Shize Bio aims to provide scalable and cost-effective regenerative medicine solutions for conditions with high unmet medical needs, such as spinal cord injury and multiple system atrophy. The company has secured significant funding from top-tier investors to advance its pipeline through clinical validation and toward commercialization.